NewzThe Singapore-based Hilleman Laboratories has announced plans to develop the rVSV Bundibugyo vaccine, a candidate currently identified as a highly promising option for preventing Ebola. The organization intends to advance the vaccine through the necessary stages to enable human clinical trials.
This development marks a significant step in the effort to address the Bundibugyo strain of the Ebola virus. By moving the candidate toward human testing, researchers aim to establish the safety and efficacy of the jab, potentially expanding the available medical countermeasures against future outbreaks.
In-depth summary · AI, neutral